The Estée Lauder Companies has acquired a minority stake in 111Skin, as it looks to expand its portfolio in premium, science-led skincare. Terms of the agreement were not disclosed.

Founded in 2012 by reconstructive surgeon Yannis Alexandrides, 111Skin is known for its clinically backed formulations, including the proprietary NAC Y2 complex which claims to support skin repair and resilience.

The brand’s portfolio spans more than 30 products, with pricing ranging from $50 to $1000.

111Skin operates across luxury retail, e-commerce and high-end spa channels, with distribution through partners such as Harrods, Bluemercury, Nordstrom, Mandarin Oriental and Aman.

Its direct-to-consumer business accounts for around 20 per cent of sales. North America represents approximately 40 per cent of its 2025 revenue, alongside a growing presence in China, the UK, Europe and Asia Pacific.

Stephanie de La Faverie, president and CEO, The Estée Lauder Companies, said the investment reflects the group’s focus on innovation in skincare. 

“Our vision underscores the opportunity to support the brand’s growth; expanding its global reach while preserving the distinctive approach that has made it so relevant with today’s consumers,” she said.

Alexandrides will remain actively involved in the business, continuing to lead the brand alongside its management team.

• Further reading: Estée Lauder seeks to buy Puig.